Cholesterol and Pharmacogenetic Study

Summary

Cholesterol and Pharmacogenetic Study is a clinical trial^[1].

Key Facts

• Cholesterol and Pharmacogenetic Study is in the country of United States^[2].
• Cholesterol and Pharmacogenetic Study's instance of is recorded as clinical trial^[3].
• Cholesterol and Pharmacogenetic Study's start time is recorded as +2002-03-31T00:00:00Z^[4].
• Cholesterol and Pharmacogenetic Study's end time is recorded as +2004-10-31T00:00:00Z^[5].
• Cholesterol and Pharmacogenetic Study's sponsor is recorded as children's hospital^[6].
• Cholesterol and Pharmacogenetic Study's main subject is recorded as coronary artery disease^[7].
• Cholesterol and Pharmacogenetic Study's number of participants is recorded as {'unit': '1', 'amount': '+1000'}^[8].
• Cholesterol and Pharmacogenetic Study's title is recorded as Cholesterol and Pharmacogenetic Study^[9].
• Cholesterol and Pharmacogenetic Study's short name is recorded as CAP^[10].
• Cholesterol and Pharmacogenetic Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+30'}^[11].
• Cholesterol and Pharmacogenetic Study's ClinicalTrials.gov ID is recorded as NCT00451828^[12].
• Cholesterol and Pharmacogenetic Study's research intervention is recorded as simvastatin/sitagliptin^[13].
• Cholesterol and Pharmacogenetic Study's clinical trial phase is recorded as phase IV clinical trial^[14].
• Cholesterol and Pharmacogenetic Study's research site is recorded as University of California, San Francisco^[15].
• Cholesterol and Pharmacogenetic Study's study type is recorded as interventional study^[16].